Edition:
United States

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,546.00GBp
6:42am EDT
Change (% chg)

-6.80 (-0.44%)
Prev Close
1,552.80
Open
1,544.00
Day's High
1,550.79
Day's Low
1,534.60
Volume
5,122,017
Avg. Vol
8,904,681
52-wk High
1,724.50
52-wk Low
1,235.20

Chart for

About

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare... (more)

Overall

Beta: 1.09
Market Cap(Mil.): £77,170.16
Shares Outstanding(Mil.): 4,959.52
Dividend: 19.00
Yield (%): --

Financials

  GSK.L Industry Sector
P/E (TTM): 36.24 29.97 34.18
EPS (TTM): 0.43 -- --
ROI: 8.95 13.65 13.17
ROE: 256.90 15.43 15.15

Kraft Heinz considering sale of Complan brand in India: Bloomberg

Kraft Heinz Co is considering a sale of children's energy drink brand Complan in India, which could fetch about $1 billion, Bloomberg reported on Monday, citing people familiar with the matter.

Jun 18 2018

Kraft Heinz considering sale of Complan brand in India - Bbg

June 18 Kraft Heinz Co is considering a sale of children's energy drink brand Complan in India, which could fetch about $1 billion, Bloomberg reported on Monday, citing people familiar with the matter.

Jun 18 2018

CORRECTED-UPDATE 1-GSK's two-drug HIV treatment meets main goal in late stage studies

June 14 GlaxoSmithKline said on Thursday that its two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies - a big win after regulators warned of possible birth defects from one of the two drugs.

Jun 14 2018

CORRECTED-GSK's two-drug HIV treatment meets main goal in late stage studies

June 14 GlaxoSmithKline said on Thursday that its two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies.

Jun 14 2018

FDA finds deficiencies in Mylan's generic Advair; shares fall

Mylan NV said on Wednesday that U.S. health regulators were unable to approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug Advair for the second time, as they found "minor deficiencies" in the treatment.

Jun 13 2018

UPDATE 2-FDA finds deficiencies in Mylan's generic Advair; shares fall

* Shares fall 4.5 pct after market (Adds analyst comment; updates shares)

Jun 13 2018

FDA finds deficiencies in Mylan's generic Advair

June 13 U.S. drugmaker Mylan NV said on Wednesday that U.S. health regulators could not approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug, Advair, and cited "minor deficiencies" with the copycat version.

Jun 13 2018

GSK says vaccine business president to leave by year-end

GlaxoSmithKline Plc said the president of its vaccines business, Luc Debruyne, would leave the company at the end of the year.

Jun 12 2018

UPDATE 1-GSK says vaccine business president to leave by year-end

June 12 GlaxoSmithKline Plc said the president of its vaccines business, Luc Debruyne, would leave the company at the end of the year.

Jun 12 2018

GSK says vaccine business president to leave by year-end

June 12 GlaxoSmithKline Plc said the president of its vaccines business, Luc Debruyne, would leave the company at the end of the year.

Jun 12 2018

Earnings vs. Estimates